Compare Amylx Pharmaceuticals Inc (AMLX) vs MPLX LP (MPLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs MPLX LP — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while MPLX LP trades at $58.43 (market cap $57.79B). The key difference: MPLX LP is far larger — about 29.2× Amylx Pharmaceuticals Inc's market cap, and MPLX LP pays a 7.56% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | MPLX | |
|---|---|---|
Market Cap | $1.98B | $57.79B |
Sector | Health | Technology |
52-Week High | $18.70 | $59.17 |
52-Week Low | $7.64 | $47.80 |
Enterprise Value | $1.70B | $82.42B |
Dividend Yield | — | 7.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
MPLX trades at $56.95, down 0.42% on the day, with a bullish technical outlook supported by moving averages and key support at $56. The company reported strong profitability with a 41.24% net income margin and a trailing P/E of 12.33. Recent earnings showed beats in Q3 and Q4 2025 but a miss in Q1 2026, with Q2 results pending. A $1.08 dividend for H1-26 underscores its income appeal, while analyst consensus remains strongly positive with a $60.60 price target.
The outlook for MPLX is favorable, driven by stable cash flows from fee-based midstream operations and a high dividend yield. Risks include exposure to energy market volatility and a high debt-to-asset ratio of 90.06%. With 71% of analysts rating it a Buy and solid fundamentals, the stock presents a compelling opportunity for income-focused investors, though macroeconomic headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
